Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 116.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 455.00 | |
25 mg | In stock | $ 763.00 | |
50 mg | In stock | $ 1,070.00 | |
100 mg | In stock | $ 1,430.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 318.00 |
Description | GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3. |
In vitro | GSK2593074A (GSK'074) (0.01, 0.1, 1, 10, and 100 nM; 6 h) fully prevents necroptosis across various stimuli in both human and murine cells with IC50~3 nM, including MOVAS cells and L929 cells.[1] |
In vivo | GSK2593074A (GSK'074) (0.93 mg/kg/day; i.p.; 14 or 28 days; mice) show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (27.36±8.25%; P<0.05). Inhibited aneurysm formation in mouse models of aneurysms.[1] |
Synonyms | GSK'074 |
Molecular Weight | 465.57 |
Formula | C27H23N5OS |
CAS No. | 1337531-06-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 41.67 mg/mL (89.50 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK2593074A 1337531-06-2 Apoptosis NF-Κb TNF RIP kinase GSK'074 GSK-2593074A inhibitor inhibit